Floatz logo

HEPARIN

Cancer of Stomach

H. Lee Moffitt Cancer Center and Research InstitutemixtureN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cancer of Stomach cohort.

Asset / SponsorPhaseRating
TEONANACATL
Psyence Australia Pty Ltd
Phase 2CCC
Minnelide
Minneamrita Therapeutics LLC
Phase 1CC
gz17-6.02
Genzada Pharmaceuticals USA, Inc.
Phase 1CC

Same molecule, other indications

HEPARIN is also rated in:

venous thromboembolismDormant
BB
Indicative ·
67 / 100
View asset →
Insulin Resistance Syndrome XDormant
BB
Indicative ·
65 / 100
View asset →
Pancreatic Beta Cell FunctionDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →